Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
April 06 2016 - 6:00AM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that Mr Glyn Edwards, Chief Executive Officer, will present at
Needham & Company’s 15th Annual Healthcare Conference, 13 April
2016 at 11:20am EDT in New York City.
A live audio webcast of the presentation will be
available through the Investors section on the Company’s website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit |
|
Glyn
Edwards / Richard Pye (UK office) |
Tel:
+44 (0)1235 443 951 |
Erik
Ostrowski / Michelle Avery (US office) |
+1
617 225 4455 |
|
|
Cairn Financial Advisers LLP |
|
(Nominated Adviser) |
|
Liam
Murray / Tony Rawlinson |
Tel:
+44 (0)20 77148 7900 |
|
|
N+1 Singer |
|
(Broker) |
|
Aubrey
Powell / Jen Boorer |
Tel:
+44 (0)20 7496 3000 |
|
|
Peckwater PR |
|
(Financial public relations, UK) |
Tel:
+44 (0)7879 458 364 |
Tarquin
Edwards |
tarquin.edwards@peckwaterpr.co.uk |
|
|
MacDougall Biomedical Communications |
|
(US
media contact) |
Tel:
+1 781 235 3060 |
Chris
Erdman |
cerdman@macbiocom.com |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024